Lipitor
Metastatic Ovarian Cancer
Tampere University HospitalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Metastatic Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TIL Inge Marie Svane | Phase 2 | BB |
Young Til National Cancer Institute (NCI) | Phase 2 | CCC |
Nerofe Immune System Key Ltd | Phase 1/2 | CCC |
Relatlimab Inge Marie Svane | Phase 1/2 | CCC |
[18f]-azafol University of Lausanne Hospitals | Phase 1 | CC |
Erx-315 EtiraRx Australia Pty Ltd | Phase 1 | CC |
METHYLAMINOLEVULINATE Institut du Cancer de Montpellier - Val d'Aurelle | N/A | D |
Same molecule, other indications
Lipitor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →